Skip to main content

Dysbiosis in Phylogenetically Diverse Species Associated With Type 2 Diabetes

Medically reviewed by Carmen Pope, BPharm. Last updated on June 26, 2024.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, June 26, 2024 -- The gut microbiome has a potential functional role in the pathogenesis of type 2 diabetes (T2D), according to a study published online June 25 in Nature Medicine.

Zhendong Mei, Ph.D., from Brigham and Women's Hospital in Boston, and colleagues analyzed 8,117 shotgun metagenomes from 10 cohorts of individuals with T2D, prediabetes, and normoglycemic status in the United States, Europe, Israel, and China in a comprehensive study of the T2D microbiome.

The researchers identified associations between dysbiosis in 19 phylogenetically diverse species with T2D; for example, enriched Clostridium bolteae and depleted Butyrivibrio crossotus. These microorganisms also contributed to community-level functional changes that may underlie pathogenesis of T2D, such as perturbations in glucose metabolism. Within-species phylogenetic diversity was identified for strains of 27 species that account for inter-individual differences in T2D risk; these were explained by strain-specific gene carriage in some cases, including loci involved in various mechanisms of horizontal gene transfer and novel biological processes underlying metabolic risk.

"Although our study does not establish causal linkages and should be interpreted as hypothesis generating, it offers the most comprehensive evidence to date of the gut microbiome's involvement in the pathogenesis of T2D from the population study perspective," the authors write. "These results lay the groundwork for future mechanistic studies."

One author disclosed ties to Zoe Nutrition, Empress Therapeutics, and Seres Therapeutics.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted June 2024

Read this next

Real-World Weight Loss With Semaglutide, Tirzepatide Less Than That Seen in Clinical Trials

THURSDAY, June 12, 2025 -- For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent on average, which is lower...

Increasing Proportion of U.S. Adults Unaware They Have Hypertension

MONDAY, June 9, 2025 -- From 2013 to 2023, there was an increase in the proportion of U.S. adults who were unaware of having hypertension, according to a research letter published...

Finerenone + Empagliflozin Offers Greater Benefit in CKD, T2DM

MONDAY, June 9, 2025 -- For patients with chronic kidney disease and type 2 diabetes, combination finerenone plus empagliflozin leads to a greater reduction in the urinary...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.